Park Ha Biological Faces Class Action Over Alleged Stock Manipulation Scheme

  • Rosen Law Firm filed a class action lawsuit against Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) on behalf of investors who purchased securities between December 27, 2024, and July 8, 2025.
  • The lawsuit alleges Park Ha misled investors regarding its business operations, including involvement in a fraudulent stock promotion scheme and artificial trading activity.
  • The firm claims Park Ha's IPO was structured with an extremely low public float to enable manipulation.
  • Lead plaintiff motions must be filed by September 28, 2026.

The lawsuit highlights growing concerns over stock manipulation in the biotech and cosmetics sectors, particularly among firms with low public floats. This case could set a precedent for how regulators and investors approach emerging market firms with similar structures. The allegations of social media-based misinformation also underscore the increasing role of digital platforms in market manipulation schemes.

Regulatory Scrutiny
How increased regulatory attention to stock manipulation schemes will impact similar biotech and cosmetics firms.
Investor Confidence
Whether Park Ha can regain investor trust following these allegations.
Legal Precedent
The pace at which similar cases against emerging market firms are resolved.